Successful outsourcing relationships for early phase analytics in drug development are driven by partnership.
Criteria for choosing an analytical services partner during the early phase of drug development include scientific skills/knowledge and resource availability, and the type of relationship developed with an analytical service provider is typically defined by customer needs. To start with, the provider of early phase analytical studies should show that they have the necessary scientific skills and knowledge to support the program in question. Discussions between client and provider are also necessary to ensure that both parties are comfortable with what is required out of the relationship.
Read this article in BioPharm International'sOutsourcing Resources 2018 eBook.
View other articles in BioPharm International's Outsourcing Resources 2018 eBook.
BioPharm International
eBook: Outsourcing Resources 2018
Vol. 31
March 2018
Pages: 27–29
When referring to this article, please cite it as F. Mirasol, " Choosing an Analytical Partner in Early Drug Development," BioPharm International Outsourcing Resources eBook (March 2018).
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.